ArticleCNS neuroscience & therapeutics2026
Concurrent Stereotactic Radiotherapy and Immune Checkpoint Inhibitors for Multiple Brain Metastases in Non-Small Cell Lung Cancer - A Multi-Center Retrospective Analysis.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the efficacy and safety of concurrent versus sequential stereotactic radiotherapy (SRT) and immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BM).
methodsWe retrospectively analyzed 198 NSCLC patients with BM who underwent SRT and ICIs treatment between 2017 and 2024. Of 136 eligible patients, were assigned to two cohorts and subcohorts through propensity score matching. The concurrent cohort consisted of 68 patients receiving ICIs within 14 days of SRT (post-SRT 34 cases and pre-SRT 34 cases). The sequential cohort included another 68 patients undergoing sequential treatment > 14 days apart (post-SRT1 31 cases and pre-SRT1 37 cases). Overall survival (OS) and intracranial progression-free survival (iPFS) were the primary endpoints. Secondary endpoints were intracranial objective response rate (iORR), disease control rate (DCR) and adverse events (AEs).
resultsConcurrent group achieved significantly superior median OS (24.5 months vs. 18.3 months, HR = 0.68, 95% CI 0.49-0.94, p = 0.001) and median iPFS (14.2 months vs. 9.8 months, HR = 0.62, 95% CI 0.45-0.86, p < 0.001) compared to the sequential group. Subgroup analysis, the post-SRT group showed significantly improved median OS (27.1 months vs. 17.2, 19.2, 13.2 months, p < 0.05) and median iPFS (20.1 months vs. 10.5, 12.1, 5.3 months, p < 0.05) compared to the other three groups (pre-SRT, post-SRT1 and pre-SRT1). Multivariate analysis revealed that a treatment interval ≤ 14 days was an independent protective factor for both iPFS (p = 0.004) and OS (p = 0.019). Subgroup analysis demonstrated that a treatment interval ≤ 7 days was superior to an interval of 8-14 days or > 14 days. Furthermore, ICIs following SRT was associated with improved OS (p = 0.003) and iPFS (p < 0.001). No significant differences were observed in radionecrosis (RN) and AEs.
conclusionConcurrent SRT with ICI, especially ICIs following SRT, provides superior survival outcomes for NSCLC patients with multiple BM, without increasing AEs. The timing of therapy is a critical factor influencing the efficacy of the combined regimen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.